• Policy
• Expanded clinical use of orphan drug 'Joenja' in children
• by Lee, Hye-Kyung Dec 6, 2024 05:56am

• Policy
• Linking 'Prior review-performance evaluation-reevaluation'
• by Lee, Tak-Sun Dec 6, 2024 05:56am

• Policy
• Astellas’s Xtandi Tab 40mg and 80mg approved in KOR
• by Lee, Hye-Kyung Dec 5, 2024 05:53am

• Policy
• 30-day negotiation window for essential medicines
• by Lee, Tak-Sun Dec 4, 2024 05:57am

• Policy
• Legislation of ‘INN prescriptions’ for drugs begin
• by Lee, Jeong-Hwan Dec 4, 2024 05:56am

• Policy
• 17 drugs receive essential medicine designations
• by Lee, Hye-Kyung Dec 3, 2024 05:53am

• Policy
• Janssen’s Tremfya’s price cut 2yrs due to increased use
• by Lee, Tak-Sun Dec 3, 2024 05:52am

• Policy
• Concerns about National Bio Committee's foreign pharma exec
• by Lee, Jeong-Hwan Nov 29, 2024 05:54am

• Policy
• KIPO opposes to objections to new drug patent extended cap
• by Lee, Jeong-Hwan Nov 28, 2024 05:55am

• Policy
• Trial for targeted drug 'VERT-002' for NSCLC begins in KOR
• by Lee, Hye-Kyung Nov 28, 2024 05:55am